Titan Pharmaceuticals (NASDAQ:TTNP) Issues Quarterly Earnings Results, Beats Estimates By $0.47 EPS

Titan Pharmaceuticals (NASDAQ:TTNP) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.86) EPS for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.47, Fidelity Earnings reports. Titan Pharmaceuticals had a negative return on equity of 986.16% and a negative net margin of 382.11%.

Shares of TTNP traded down $0.09 during trading hours on Thursday, reaching $2.89. 3,596 shares of the company traded hands, compared to its average volume of 1,700,327. The stock has a market capitalization of $20.63 million, a P/E ratio of -0.39 and a beta of 0.98. The company has a quick ratio of 0.95, a current ratio of 1.13 and a debt-to-equity ratio of 2.14. Titan Pharmaceuticals has a 12-month low of $2.56 and a 12-month high of $14.06. The business has a fifty day moving average price of $3.32 and a 200-day moving average price of $3.83.

Separately, Maxim Group raised shares of Titan Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Thursday, February 25th.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism.

Featured Article: What are the most popular ETFs

Earnings History for Titan Pharmaceuticals (NASDAQ:TTNP)

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.